Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

August 01, 2015 9:19 PM ET


Company Overview of Kinex Pharmaceuticals, Inc.

Company Overview

Kinex Pharmaceuticals, Inc., a biotechnology company, develops and commercializes therapies for cancer and immunomodulatory diseases. Its products include Oraxol, an oral formulation of paclitaxel for oral delivery of paclitaxel when combined with HM30181, an absorption enhancer and P-glycoprotein pump inhibitor; and Oratecan, an oral formulation of Irinotecan for oncology indications, such as colorectal cancers. The company’s products also include KX01 (KX2-391), a synthetic, orally active and highly selective inhibitor of Src tyrosine kinase signaling and tubulin polymerization; and KX02 (KX2-361), a dual Src/pre-tubulin inhibitor and a small molecule drug that shows potent inhibitory acti...

701 Ellicott Street

Buffalo, NY 14203

United States

Founded in 2003





Key Executives for Kinex Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 54
Co-Founder and Chief Scientific Officer
Chief Operating Officer and Director
Age: 49
President of Quadpharma
Chief Medical Officer
Compensation as of Fiscal Year 2015.

Kinex Pharmaceuticals, Inc. Key Developments

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in Phase 1 Clinical Study

Kinex Pharmaceuticals announced that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. KX2-391 (KX01), a dual Src/pre-tubulin inhibitor, is a small molecule drug that has excellent skin penetration when formulated as a topical ointment. The pre-tubulin activity causes hyperproliferating cells to undergo apoptosis due to a disruption of the tubulin dynamics needed for these cells to pass through mitosis. Actinic Keratosis (AK) is a very common skin disease that appears as rough, dry, scaly patches or growths that form on the skin when the skin is badly damaged by ultraviolet rays from the sun or through indoor tanning. Ultraviolet rays can cause damage to DNA and RNA leading to keratinocyte mutations and uncontrolled growth. Reduction of the tumor suppressor p53 level has also been implicated in the unchecked proliferation of dysplastic keratinocytes. KX2-391 also potently increases p53 levels during unchecked proliferation thereby potentially addressing the dysregulation of p53 in AK.

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in A Phase 1 Clinical Study

Kinex Pharmaceuticals announced that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. KX2-361 (KX02), a dual src/pre-tubulin inhibitor, is a small molecule drug that has shown potent inhibitory activity against a broad panel of brain tumor cell lines, including those that are resistant to Temozolomide (T98G), the most widely used chemotherapy for the treatment of malignant glioma. In a well-established brain tumor mouse model, KX2-361 consistently clears brain tumors after 4 weeks of therapy, in 30-60% of treated animals. These studies showed that KX2-361 induced significant necrosis compared to Temodar, and the treated animals also generated an immune response to the glioblastoma tumor cells. Pharmacokinetic studies have demonstrated that KX2-361 is absorbed orally and has approximately 75% penetration into brain tissue from plasma. Kinex Pharmaceuticals has also received Orphan Drug designation for KX2-361 for the treatment of gliomas, which are the most common and aggressive form of brain cancer. A Phase 1 clinical trial for KX2-361 has commenced at Roswell Park Cancer Institute and the Cleveland Clinic. A third site has been identified and will initiate during the fourth quarter of 2014. Dosing of the first patient has taken place at Roswell Park Cancer Institute where enrollment is expected to be robust based on the unique mechanism of action of this drug as well as the pre-clinical data that has been generated.

Kinex Pharmaceuticals Appoints Flint Besecker as Chief Operating Officer

Kinex Pharmaceuticals announced that Mr. Flint Bese cker has been appointed Chief Operating Officer of the company. Mr. Besecker will have additional responsibility over Kinex's emerging global operating platforms in addition to all corporate business matters reporting to Kinex's Chief Executive Officer, Dr. Johnson Lau. More recently, Flint served as Chief Business Officer and has been Executive Vice-President and Chief Financial Officer of Kinex since July 2013 and a Board member since 2011.

Similar Private Companies By Industry

Company Name Region
One Cell Systems, Inc. United States
Berkeley Bioengineering Co. United States
Nutech Medical, Inc. United States
Choncept LLC United States
Afferent Pharmaceuticals, Inc. United States

Recent Private Companies Transactions

Private Placement
March 26, 2015
September 9, 2014
QuaDPharma, Inc.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Kinex Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at